ArticleMicroorganisms2019
Nontuberculous Mycobacteria Persistence in a Cell Model Mimicking Alveolar Macrophages.
Article in Microorganisms, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 22 citations in OpenAlex.
- Bedaquiline for treatment of non-tuberculous mycobacteria (NTM): a systematic review and meta-analysis.The Journal of antimicrobial chemotherapy · 2024Pooled it
- Acidic pH Restricts Non-Tuberculous Mycobacteria Replication.Molecular microbiology · 2026Article
- Nintedanib Enhances the Antibacterial Activity of Bedaquiline Against Non-Tuberculous Mycobacteria: In vitro and in Mice Models.Infection and drug resistance · 2026Article
- Characterization of novel mycobacteriophages with a focus on phage Pisa4 and its interaction with human innate immune cells.Frontiers in microbiology · 2026Article
- Identification of apoptosis-related genes as potential biomarkers and therapeutic targets in cystic fibrosis patients progressing to pulmonary nontuberculous mycobacterial disease.Scientific reports · 2025Article
- The microbiome and gut-lung axis in nontuberculous mycobacterial pulmonary disease.PLoS pathogens · 2025Review
- In vivo antimicrobial activity of engineered mesoporous silica nanoparticles targeting intracellular mycobacteria.Nature communications · 2025Article
- Microvesicles Derived from Human Bronchial Epithelial Cells Regulate Macrophage Activation DuringJournal of proteome research · 2025Article
- Repurposing of apoptotic inducer drugs against Mycobacterium tuberculosis.Scientific reports · 2025Article
- Characterization of Exosomes Released from Mycobacterium abscessus-Infected Macrophages.Proteomics · 2025Article
- Antimycobacterial activity of intertidal sediment-derived bacteria from False Bay, South Africa.Frontiers in microbiology · 2025Article
- MptpB Inhibitor Improves the Action of Antibiotics againstACS infectious diseases · 2024Article
- Hacking the Immune Response to Solid Tumors: Harnessing the Anti-Cancer Capacities of Oncolytic Bacteria.Pharmaceutics · 2023Review
- Meeting the challenges of NTM-PD from the perspective of the organism and the disease process: innovations in drug development and delivery.Respiratory research · 2022Review
- Exacerbation ofVirulence · 2021Article
- Liposomal drug delivery to manage nontuberculous mycobacterial pulmonary disease and other chronic lung infections.European respiratory review : an official journal of the European Respiratory Society · 2021Review
- Non-tuberculous mycobacteria immunopathogenesis: Closer than they appear. a prime of innate immunity trade-off and NTM ways into virulence.Scandinavian journal of immunology · 2021Review
- Autophagy and Host Defense in Nontuberculous Mycobacterial Infection.Frontiers in immunology · 2021Review
- Non-Tuberculous Mycobacteria: Molecular and Physiological Bases of Virulence and Adaptation to Ecological Niches.Microorganisms · 2020Review
- Differential Responses by Human Macrophages to Infection WithFrontiers in microbiology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nontuberculous Mycobacteria (NTM) respiratory infections have been gradually increasing. Here, THP-1 cells were used as a model to evaluate intracellular persistence of three NTM species (reference and clinical strains) in human alveolar macrophages. The contribution of phagosome acidification, nitric oxide (NO) production and cell dead on NTM intracellular fate was assessed. In addition, strains were characterized regarding their repertoire of virulence factors by whole-genome sequencing. NTM experienced different intracellular fates:
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.